AP NEWS

Global Genital Herpes Treatment Drugs Market Size & Share, Application Analysis, Growth Trends, Key Players, Competitive Strategies and Forecasts to 2026 - ResearchAndMarkets.com

February 6, 2019

DUBLIN--(BUSINESS WIRE)--Feb 6, 2019--The “Global Genital Herpes Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026” report has been added to ResearchAndMarkets.com’s offering.

The global genital herpes treatment drugs market is expected to expand at a CAGR of 4.9% from 2018 to 2026.

There is a changing trend in the treatment of genital herpes infection, wherein biologist is primarily focusing on developing vaccines to bolster immunity in ailing patients and address the problem of lesion recurrence.

Acyclovir is presently dominating the drug class for the genital herpes treatment drugs market. The primary features responsible for the dominance of acyclovir are its excellent therapeutic efficacy, dose tolerance with negligible toxicity. It is currently the drug of the first choice for the treatment of genital herpes with a prescribed dose of 200 mg five times daily for 10 days.

Famciclovir has gained prominence on account of its higher oral bioavailability which is employed for the treatment of genital herpes patients suffering from lesion recurrence.

North America is currently reigning the geographical segment for genital herpes treatment drugs market. According to the Center for Disease Control and Prevention (CDC), genital herpes is occurring 1in every 6 citizens in the United States. The rising prevalence of sexually transmitted disease and effective treatment guidelines drive the genital herpes treatment drugs market growth in North America.

Affordable reimbursement scenario and domicile of major players such as AstraZeneca, GlaxoSmithKline and Novartis propel the genital herpes treatment drugs market growth in the European region.

Asia Pacific will register rapid growth during the forecast period from 2018 to 2026 owing to the rising prevalence of HSV-1 infected patients, increasing public health awareness and presence of huge generic drugs for the treatment of genital herpes infection.

Key Market Movements

The rising prevalence of sexually transmitted disease worldwide Increasing public health awareness and affordable reimbursement scenario drive the genital herpes treatment drugs market Excellent product pipeline catering therapeutics vaccines to bolster patient immunity such as GEN-003 and VCL-HB01

Topics Covered

Chapter 1. Preface

1.1. Report Scope and Description

1.2. Research Scope

1.3. Research Methodology

1.4. Market Segmentation

Chapter 2. Executive Summary

2.1. Global Genital Herpes Treatment Drugs Market Portraiture

2.2. Global Genital Herpes Treatment Drugs Market, by Drug Class, 2017 (US$ Mn)

2.3. Global Genital Herpes Treatment Drugs Market, by Geography, 2017 (US$ Mn)

Chapter 3. Genital Herpes Treatment Drugs Market: Dynamics and Future Outlook

3.1. Market Overview

3.2. Drivers

3.3. Challenges

3.4. Opportunities

3.5. Attractive Investment Proposition, by Geography, 2017

3.6. Competitive Analysis: Global Genital Herpes Treatment Drugs Market, by Key Players, 2017

Chapter 4. Global Genital Herpes Treatment Drugs Market, by Drug Class

4.1. Overview

4.2. Acyclovir

4.3. Famciclovir

4.4. Valacyclovir

4.5. Pipeline Analysis

Chapter 5. Global Genital Herpes Treatment Drugs Market, by Geography

5.1. Overview

5.2. North America Genital Herpes Treatment Drugs Market Analysis, 2016-2026

5.3. Europe Genital Herpes Treatment Drugs Market Analysis, 2016-2026

5.4. Asia Pacific Genital Herpes Treatment Drugs Market Analysis, 2016-2026

5.5. Latin America Genital Herpes Treatment Drugs Market Analysis, 2016-2026

5.6. Middle East and Africa Genital Herpes Treatment Drugs Market Analysis, 2016-2026

Chapter 6. Company Profiles

6.1. AstraZeneca PLC

6.2. Apotheca Inc.

6.3. Asahi Kasei Pharma Corporation

6.4. Carlsbad Technology Inc.

6.5. GlaxoSmithKline PLC

6.6. Mylan N.V.

6.7. Novartis AG

6.8. Merck & Co. Inc.

6.9. Teva Pharmaceutical Industries Ltd.

6.10. Zydus Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/research/rkvg42/global_genital?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190206005368/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs,Infectious Disease Testing,Sexual and Reproductive Health Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/06/2019 08:00 AM/DISC: 02/06/2019 08:01 AM

http://www.businesswire.com/news/home/20190206005368/en

AP RADIO
Update hourly